Tetramethylpyrazine Nitrone

硝酮嗪

Report date: 2023/12/19 20:05:05
NME

Base Information

Drug NameTetramethylpyrazine Nitrone
Drug Alias NameTBNTetramethylpyrazine Nitrone (Guangzhou Magpie Pharmaceuticals)Nitoxazine (Guangzhou Magpie Pharmaceutical)Nitrazine (Guangzhou Magpie Pharmaceutical)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionBrain-derived neurotrophic factor agonistsProto-oncogene proteins c-akt modulators
TargetsBrain-derived neurotrophic factorProto-oncogene proteins c-akt
Therapy Area/IndicationsIschemic StrokeDiabetes Mellitus, Type 2Diabetic Nephropathies +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesJinan University
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesGuangzhou Magpie Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsIschemic StrokeDiabetes Mellitus, Type 2Diabetic Nephropathies +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A